Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-24T14:47:37.144Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacotherapy of Borderline Personality Disorder: A Metaanalysis of Randomised Controlled Trials [PW01-02]

Published online by Cambridge University Press:  16 April 2020

J. Stoffers ,
B. Völlm ,
G. Rücker ,
A. Timmer  and
K. Lieb
J. Stoffers
Affiliation:
Department of Psychiatry and Psychotherapy, University Hospital Freiburg, Freiburg im Breisgau, Germany Department of Psychiatry and Psychotherapy, Clinical Centre of the Johannes-Gutenberg-University of Mainz, Mainz, Germany
B. Völlm
Affiliation:
Section of Forensic Mental Health, Division of Psychiatry, University of Nottingham, Nottingham, UK
G. Rücker
Affiliation:
German Cochrane Centre, Department of Medical Biometry and Statistics, University Hospital Freiburg, Freiburg im Breisgau, Germany
A. Timmer
Affiliation:
German Cochrane Centre, Department of Medical Biometry and Statistics, University Hospital Freiburg, Freiburg im Breisgau, Germany
K. Lieb
Affiliation:
Department of Psychiatry and Psychotherapy, Clinical Centre of the Johannes-Gutenberg-University of Mainz, Mainz, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

In Borderline Personality Disorder (BPD), pharmacotherapy is used for the treatment of specific BPD pathology facets, such as cognitive-perceptual, affective, or impulsivity symptoms. Due to the polymorphic phenomenology of the disorder, different classes of drugs are used, e.g., antipsychotics, antidepressants, or mood stabilizers.

Aims:

To evaluate the up-to-date evidence of drug treatment efficacy for BPD.

Method:

A systematic review and metaanalysis of randomised controlled trials was done. All randomised comparisons of drug vs. placebo, drug vs. drug, or drug vs. a combination of drugs in adult BPD patients were eligible for inclusion. Outcomes comprised BPD core pathology as depicted by DSM criteria, associated pathology, i.e., depression and anxiety, general measures of overall psychopathology severity and mental health status, tolerability, and adverse effects. With support of the Cochrane Collaboration, a thorough search was conducted to identify both published and unpublished trials. The findings were scrutinized by two reviewers independently.

Results:

Twenty-six trials were included, investigating first- and second-generation antipsychotics, mood stabilizers, antidepressants, and omega-3 fatty acids.

Conclusion:

Findings indicate beneficial effects for all classes of drugs investigated, and suggest mood stabilizers and second-generation antipsychotic agents as first-line treatments for BPD due to their efficacy in the treatment of different domains of BPD and associated pathology. However, psychotherapeutic treatment should clearly be targeted at predefined specific symptoms.

Type
PW01-02
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E339
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.